Clinical Trial

PRediction Of Glycemic RESponse Study

Study acronym: PROGRESS
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of PROGRESS is to engage and intensively monitor 1000 individuals' dietary intake, activity levels, and continuous glucose values over 10 days, link to clinical events out to 3-years, and use that data along with genomic, microbiome, electronic health record (EHR), and other biomarker data to develop a predictive model of individual glucose responses to nutrient intake in individuals with and without type 2 diabetes.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2021-05-06; most recent amendment 2025-05-15.
Status change: Recruiting → Active, Not Recruiting 2023-11-20
Status change: Not Yet Recruiting → Recruiting 2021-07-12
Trial Details
NCT Number NCT04881019
Lead Sponsor Scripps Translational Science Institute
Collaborators: CareEvolution Healthcare Technology, Tempus AI
Conditions Glycemic Response
Enrollment 1,070 participants
Start Date 2021-06-08
Primary Completion 2023-09-01 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-21